Topotecan (Hycamtin) is a promising new topoisomerase I-targeting anticancer agent that first entered clinical trials in 1989 under National Cancer Institute sponsorship in collaboration with SmithKline Beecham. In 1996, it
Susan G. Arbuck, MD
Advertisement
Articles by Susan G. Arbuck, MD
Advertisement
Latest Updated Articles
- Clinical Status and Optimal Use of Topotecan
Published: November 1st 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
5
